Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone
Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.
How this was made
The 30-second read
Why it matters
The beat-and-raise and the explicit EBITDA milestone likely drive the immediate repricing, while the market’s next focus is whether 2027 EBITDA can avoid the expected decline amid Medicare reimbursement pressure.
Market read
Traders can use the raised EBITDA framework and the 2027 Medicare sensitivity as a read-across into AbbVie’s upcoming earnings and to position for longer-dated generic-entry optionality in Teva.
What to watch
The article flags an expected EBITDA decline into 2027; traders may be underweighting the magnitude of that step-down versus the near-term beat and debt reduction.
Background
Bausch’s quarter is driven by Xifaxan and Salix growth, with Medicare price changes taking effect in 2027 and requiring gross-to-net accrual adjustments.
Ticker impact
Bausch Health shares jumped 21% after adjusted EPS of $1.77 beat estimates and it raised full-year outlook, citing EBITDA milestone and Xifaxan Medicare pricing.
Likely sustained support while traders price the raised outlook, but volatility around 2027 EBITDA expectations.
The article attributes the move to a beat-and-raise with specific adjusted EPS, revenue, and raised EBITDA target, while flagging 2027 as the next test due to expected EBITDA decline.
AbbVie is flagged as facing Medicare price pressure on Vraylar and Linzess in 2027, with investors watching whether it will mirror Bausch’s channel/inventory adjustment.
Near-term sentiment likely neutral, but downside risk could rise into AbbVie’s later earnings if management signals similar Medicare impacts.
The article does not report AbbVie results, but it highlights a specific 2027 Medicare exposure and notes AbbVie reports later this week, making it a catalyst for expectations.
Teva is noted to gain the right to sell a generic Xifaxan from 2028, with the article framing it as a meaningful brand opportunity.
Likely modest positive longer-dated sentiment, but near-term price action depends on whether investors focus on 2028 entry versus current generics weakness.
The article provides a concrete 2028 generic right and mentions prior generics revenue decline, but it is not a new Teva-specific financial disclosure.
Market effects
Highlights Medicare pricing and gross-to-net mechanics as a key earnings sensitivity for pharma brands facing reimbursement changes, increasing scrutiny of 2027 guidance.
Primarily US pharma earnings and reimbursement narrative, likely influencing US large-cap pharma sentiment into the next earnings cycle.
US Medicare reimbursement changes can affect global pricing expectations and investor models for multinational pharma portfolios.
Counterpoint
The raised EBITDA target already accounts for the 2027 Medicare hit, so the stock’s upside may be more about timing than fundamental improvement, leaving limited incremental surprise for 2027.
Key entities
- companyBausch Health
NYSE-listed issuer whose adjusted EPS beat and raised EBITDA outlook drove a 21% jump, with Xifaxan Medicare pricing as the key driver.
- companyAbbVie
NYSE-listed pharma company with Medicare exposure on Vraylar and Linzess in 2027, with earnings later this week as a catalyst.
- companyTeva Pharmaceutical Industries
NYSE-listed pharma company with a right to sell a generic Xifaxan from 2028, framed as a potential brand opportunity.
